Cargando…

Geometric tumor embolic budding characterizes inflammatory breast cancer

PURPOSE: Inflammatory breast cancer (IBC) is characterized by numerous tumor emboli especially within dermal lymphatics. The explanation remains a mystery. METHODS: This study combines experimental studies with two different IBC xenografts with image algorithmic studies utilizing human tissue microa...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Arnav P., Nguyen, Julie P. T., Wang, Justin, Ahn, Jonathan S., Libling, William A., Klein, Jacob M., Mazumder, Preeanka, Barsky, Sanford H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734724/
https://www.ncbi.nlm.nih.gov/pubmed/36473978
http://dx.doi.org/10.1007/s10549-022-06819-6
_version_ 1784846631612448768
author Modi, Arnav P.
Nguyen, Julie P. T.
Wang, Justin
Ahn, Jonathan S.
Libling, William A.
Klein, Jacob M.
Mazumder, Preeanka
Barsky, Sanford H.
author_facet Modi, Arnav P.
Nguyen, Julie P. T.
Wang, Justin
Ahn, Jonathan S.
Libling, William A.
Klein, Jacob M.
Mazumder, Preeanka
Barsky, Sanford H.
author_sort Modi, Arnav P.
collection PubMed
description PURPOSE: Inflammatory breast cancer (IBC) is characterized by numerous tumor emboli especially within dermal lymphatics. The explanation remains a mystery. METHODS: This study combines experimental studies with two different IBC xenografts with image algorithmic studies utilizing human tissue microarrays (TMAs) of IBC vs non-IBC cases to support a novel hypothesis to explain IBC’s sina qua non signature of florid lymphovascular emboli. RESULTS: In the human TMAs, compared to tumor features like nuclear grade (size), mitosis and Ki-67 immunoreactivity which show that IBC is only modestly more proliferative with larger nuclei than non-IBC, what really sets IBC apart is the markedly greater number of tumor emboli and distinctly smaller emboli whose numbers indicate geometric or exponential differences between IBC and non-IBC. In the experimental xenograft studies, Mary-X gives rise to tight spheroids in vitro which exhibit dynamic budding into smaller daughter spheroids whereas Karen-X exhibits only loose non-budding aggregates. Furthermore Mary-X emboli also bud dramatically into smaller daughter emboli in vivo. The mechanism that regulates this involves the generation of E-cad/NTF1, a calpain-mediated cleavage 100 kDa product of 120 kDa full length membrane E-cadherin. Inhibiting this calpain-mediated cleavage of E-cadherin by blocking either the calpain site of cleavage (SC) or the site of binding (SB) with specific decapeptides that both penetrate the cell membrane and mimic either the cleavage site or the binding site on E-cadherin, inhibits the generation of E-cad/NTF1 in a dose-dependent manner, reduces spheroid compactness and decreases budding. CONCLUSION: Since E-cad/NFT1 retains the p120ctn binding site but loses the α-and β-catenin sites, promoting its 360° distribution around the cell’s membrane, the vacilating levels of this molecule trigger budding of both the spheroids as well as the emboli. Recurrent and geometric budding of parental emboli into daughter emboli then would account for the plethora of emboli seen in IBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06819-6.
format Online
Article
Text
id pubmed-9734724
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-97347242022-12-12 Geometric tumor embolic budding characterizes inflammatory breast cancer Modi, Arnav P. Nguyen, Julie P. T. Wang, Justin Ahn, Jonathan S. Libling, William A. Klein, Jacob M. Mazumder, Preeanka Barsky, Sanford H. Breast Cancer Res Treat Preclinical Study PURPOSE: Inflammatory breast cancer (IBC) is characterized by numerous tumor emboli especially within dermal lymphatics. The explanation remains a mystery. METHODS: This study combines experimental studies with two different IBC xenografts with image algorithmic studies utilizing human tissue microarrays (TMAs) of IBC vs non-IBC cases to support a novel hypothesis to explain IBC’s sina qua non signature of florid lymphovascular emboli. RESULTS: In the human TMAs, compared to tumor features like nuclear grade (size), mitosis and Ki-67 immunoreactivity which show that IBC is only modestly more proliferative with larger nuclei than non-IBC, what really sets IBC apart is the markedly greater number of tumor emboli and distinctly smaller emboli whose numbers indicate geometric or exponential differences between IBC and non-IBC. In the experimental xenograft studies, Mary-X gives rise to tight spheroids in vitro which exhibit dynamic budding into smaller daughter spheroids whereas Karen-X exhibits only loose non-budding aggregates. Furthermore Mary-X emboli also bud dramatically into smaller daughter emboli in vivo. The mechanism that regulates this involves the generation of E-cad/NTF1, a calpain-mediated cleavage 100 kDa product of 120 kDa full length membrane E-cadherin. Inhibiting this calpain-mediated cleavage of E-cadherin by blocking either the calpain site of cleavage (SC) or the site of binding (SB) with specific decapeptides that both penetrate the cell membrane and mimic either the cleavage site or the binding site on E-cadherin, inhibits the generation of E-cad/NTF1 in a dose-dependent manner, reduces spheroid compactness and decreases budding. CONCLUSION: Since E-cad/NFT1 retains the p120ctn binding site but loses the α-and β-catenin sites, promoting its 360° distribution around the cell’s membrane, the vacilating levels of this molecule trigger budding of both the spheroids as well as the emboli. Recurrent and geometric budding of parental emboli into daughter emboli then would account for the plethora of emboli seen in IBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06819-6. Springer US 2022-12-06 2023 /pmc/articles/PMC9734724/ /pubmed/36473978 http://dx.doi.org/10.1007/s10549-022-06819-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Preclinical Study
Modi, Arnav P.
Nguyen, Julie P. T.
Wang, Justin
Ahn, Jonathan S.
Libling, William A.
Klein, Jacob M.
Mazumder, Preeanka
Barsky, Sanford H.
Geometric tumor embolic budding characterizes inflammatory breast cancer
title Geometric tumor embolic budding characterizes inflammatory breast cancer
title_full Geometric tumor embolic budding characterizes inflammatory breast cancer
title_fullStr Geometric tumor embolic budding characterizes inflammatory breast cancer
title_full_unstemmed Geometric tumor embolic budding characterizes inflammatory breast cancer
title_short Geometric tumor embolic budding characterizes inflammatory breast cancer
title_sort geometric tumor embolic budding characterizes inflammatory breast cancer
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734724/
https://www.ncbi.nlm.nih.gov/pubmed/36473978
http://dx.doi.org/10.1007/s10549-022-06819-6
work_keys_str_mv AT modiarnavp geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT nguyenjuliept geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT wangjustin geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT ahnjonathans geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT liblingwilliama geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT kleinjacobm geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT mazumderpreeanka geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer
AT barskysanfordh geometrictumorembolicbuddingcharacterizesinflammatorybreastcancer